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Abstract
Background: The policy to provide oral polio vaccine (OPV) at birth was introduced in low-income countries to increase
coverage. The effect of OPV at birth on overall child mortality was never studied. During a trial of vitamin A
supplementation (VAS) at birth in Guinea-Bissau, OPV was not available during several periods. We took advantage of this
‘‘natural experiment’’ to test the effect on mortality of receiving OPV at birth.
Methodology: Between 2002 and 2004, the VAS trial randomised normal-birth-weight infants to 50,000 IU VAS or placebo
administered with BCG. Provision of OPV at birth was not part of the trial, but we noted whether the infants received OPV or
not. OPV was missing during several periods in 2004. We used Cox proportional hazards models to compute mortality rate
ratios (MRR) of children who had received or not received OPV at birth.
Principal Findings: A total of 962 (22.1%) of the 4345 enrolled children did not receive OPV at birth; 179 children died within
the first year of life. Missing OPV at birth was associated with a tendency for decreased mortality (adjusted MRR=0.69 (95%
CI=0.46–1.03)), the effect being similar among recipients of VAS and placebo. There was a highly significant interaction
between OPV at birth and sex (p=0.006). Not receiving OPV at birth was associated with a weak tendency for increased
mortality in girls (1.14 (0.70–1.89)) but significantly decreased mortality in boys (0.35 (0.18–0.71)).
Conclusions: In our study OPV at birth had a sex-differential effect on mortality. Poliovirus is almost eradicated and OPV at
birth contributes little to herd immunity. A randomised study of the effect of OPV at birth on overall mortality in both sexes
is warranted.
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Introduction
In low-income countries, the World Health Organization
(WHO) recommends oral polio vaccine (OPV) at birth and in 3
doses together with diphtheria-tetanus-pertussis (DTP) vaccines at
6, 10, and 14 weeks of age [1]. Furthermore, OPV has been
delivered in campaigns to children aged 6 months to 5 years of age
as part of the attempt to eradicate polio infection. The policy to
provide OPV at birth was introduced more than 20 years ago to
increase the coverage for OPV [2]. OPV at birth might also be
associated with increased antibody titres [3,4]. However, the effect
of OPV at birth on overall child mortality was never studied.
Routine vaccinations in childhood may have non-specific and
sex-differential effects on overall mortality [5–8]. The effects are
large and may strongly influence overall mortality and seriously
distort female- male mortality ratios in high-mortality settings. Our
previous work has concentrated on measles vaccine (MV) and
BCG vaccine, which are associated with decreased overall
mortality and decreased female-male mortality ratios [5,6], and
DTP vaccine, which has been associated with increased female-
male mortality ratios [7,8]. Furthermore, we also conducted one
study of an OPV campaign; receiving OPV in the campaign
compared with not receiving OPV was associated with signifi-
cantly decreased mortality among the youngest children [9]. At
the national hospital in Guinea-Bissau, following periods with
DTP being unavailable, patients having received OPV only and
no DTP had significantly lower in-hospital mortality than patients
having received both the recommended DTP and OPV [10]. The
results suggest that OPV might also have non-specific beneficial
effects on mortality.
We recently conducted a large vitamin A supplementation trial
in Guinea-Bissau. Children were randomised to 50,000 IU
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Hence, all children received BCG at enrolment. All children
should also receive OPV according to current recommendations.
However, during the last year of the trial the national
immunization programme experienced several periods during
which OPV was not available. We took advantage of this ‘‘natural
experiment’’ to test the effect of receiving OPV at birth on infant
mortality. Our a priori hypothesis was that not receiving OPV at
birth would increase mortality, particularly for girls.
Methods
Setting
The Bandim Health Project (BHP) has a demographic
surveillance system (DSS) which covers approximately 90,000
inhabitants in six suburban districts of the capital of Guinea-Bissau.
All houses are visited monthly to register new pregnancies and
births. Children are followed with home visits every third month to
register vaccinations, infections, hospitalisations, feeding patterns
and survival. The study area is economically poor. Most people live
in multi-family mud-brick houses with zinc or straw roofs. More
than 60%have no electric installations inthe house. Around30%of
the mothers in the present trial had no education. During the trial,
the prevalence of HIV-1 was around 5% in the study area among
women of fertile age [12]. A large proportion of pregnant women
are screened for HIV to prevent vertical transmission. With the
vertical-transmission control program ongoing, we expect less than
1% of the children to be HIV-1 infected.
Vitamin A trial
Participants. As described in detail elsewhere [11] the
vitamin A trial took place from November 13, 2002 to
November 28, 2004. It enrolled infants who came for the BCG
vaccination recommended at birth. The inclusion criteria were
weight $2500 g at presentation for BCG vaccination and no signs
of overt illness/malformations. It was not a criterion that the child
should receive OPV at birth. Mothers giving birth at the maternity
wards at the national hospital and the local health centre were
offered BCG and enrolment immediately after the delivery.
Mothers who delivered at home were invited to participate when
they came for BCG at two of the three health centres in the study
area. The third health centre in the study area was not enrolling
children for logistic reasons. A total of 1181 (27%) of the children
came after the first week of life; their median age at enrolment was
16 days (10–90 centiles=9–64 days).
Randomisation. Details regarding the trial were explained to
the mother by a trained assistant, who also asked the mother if she
had any questions about the study. Oral consent was obtained.
Written consent was obtained if the mother knew how to write her
own name. If not, a statement that she had understood the
information given and agreed to participate was signed by the
assistant. The mother drew a lot from an envelope prepared by the
study supervisor. Each envelope contained 100 lots, 50 marked ‘‘1’’,
and50marked‘‘2’’,indicatingfromwhichoftwonumberedbottles,
‘‘1’’ or ‘‘2’’, the child should receive its supplement. Hence, half of
the children received 50,000 IU vitamin A as retinyl palmitate and
20 IU vitamin E in K ml vegetable oil, the other half received only
20 IU vitamin E in K ml vegetable oil. The code was only opened
when all children had reached 12 months of age.
Outcomes examined. All children were followed through
the DSS every third month and were visited by a special team at
12 months of age. Deaths were registered at each visit and
followed by a verbal autopsy conducted by a trained local
physician. The physician used a questionnaire designed by the
INDEPTH network [13]. Based on the questionnaire a panel of
three medical doctors, including at least one local doctor, all being
ignorant of the randomisation group, reached consensus on the
cause of death. If consensus could not be reached a fourth doctor
was consulted. Deaths were categorised based on suggestions from
the WHO [14]. No death within the first year was due to accident.
The BHP registers hospitalisations of children from the study area
at the paediatric department of the nearby national hospital. By
linking the trial database with the hospitalisation database we were
able to identify trial children who had been hospitalised.
Current study
All trial infants were vaccinated intradermally in the upper left
deltoid region with 0.05 ml BCG vaccine (Statens Serum Institut,
Copenhagen, Denmark). The BHP provided BCG vaccine for the
trial participants. According to recommendations all infants should
also receive OPV at birth. OPV is administered orally. During the
study three types of OPV were used in Guinea-Bissau, produced
by Novartis, Sanofi Pasteur, and GlaxoSmithKline. All vaccines
were supplied through the national immunization programme.
However, OPV was missing during periods of the trial. Hence, the
children who were BCG vaccinated during these periods would
only receive BCG and not OPV. As part of our trial routines, we
noted at the inclusion form whether the children received OPV or
not. Based on the distribution of children who had not received
OPV, OPV was missing at one or more inclusion sites 1) from the
beginning of February 2004 to the beginning of June 2004, 2)
briefly in late June 2004, and 3) from mid-October 2004 to the
trial enrolment ended in November 2004 (Figure 1). Hence, all
non-OPV recipients were enrolled in 2004. We tested the
mortality levels among OPV recipients in 2002, 2003, and 2004.
The mortality levels were the same during all three years
(p=0.754). Furthermore, the female-male mortality rate ratio
among OPV recipients was the same throughout the whole study
period (p=0.799). Hence, we included all children in the analysis.
Statistical analysis
We compared baseline characteristics of children who had or
who had not received OPV at birth in a logistic regression analysis
including all variables in order to identify important potential
confounders, which could be adjusted for in subsequent analyses.
In the main analyses we studied the effect of not receiving OPV at
birth on the following three outcomes: mortality, hospitalisationand
risk of dying when hospitalised (hospital case-fatality). All analyses
wereconductedincludingallchildrenaswellasstratifiedbysex,and
without and with adjustment for potential confounders.
Mortality. We compared mortality rates of children who had
or who had not received OPV at birth in Cox proportional
hazards models [15] providing mortality rate ratios (MRR) with
95% confidence intervals (CI). Age was used as the underlying
time. Hence, age is inherently controlled for in all analyses. Infants
provided follow-up time from enrolment until they reached 12
months of age, moved, or died.
Hospitalisation. Incidence rates of hospitalisation were also
compared in Cox models with age as the underlying time providing
incidence rate ratios (IRR) with 95% CI. Multiple events were
allowed, accounting for dependence within individuals using robust
variance estimates. Infants provided follow-up time from enrolment
until they reached 12 months of age, moved, or died.
Hospital case-fatality was compared using a Poisson
regression model with robust variance estimates providing relative
risks with 95% CI [16].
We aimed to study potential effect modification. Effect
modification was analysed by investigating the homogeneity of
OPV at Birth and Mortality
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modifier using Wald test statistics. Hence, we obtained p-values for
equal effect of receiving or not receiving OPV in different strata of
a covariable. When addressing the effect of OPV according to
birth weight and arm circumference, we restricted the analysis to
children enrolled on day 0 and 1 (N=2572) for whom information
on birth characteristics was available and dichotomised the
anthropometric measurements into the lowest quartile and the
three highest quartiles.
Test for proportionality of hazard rates were computed using
Schoenfeldt residuals and by visual inspection of the Nelson-
Aalens estimator.
Results
A total of 962 children (22.1%) of the 4345 enrolled children did
not receive OPV at birth (Appendix S1). There were significant
differences between those who did and those who did not receive
OPV at birth (Table 1). Not having received OPV at birth was
associated with low age at enrolment, no maternal school
education, low arm circumference, being enrolled at the Belem
Health Centre, and dry season (Table 1). Missing OPV at birth
was not associated with length, maternal arm circumference or the
frequency of subsequent vaccinations (data not shown).
Mortality
A total of 179 children died within the first year of life. Missing
OPV at birth was associated with a tendency for decreased
mortality from enrolment to age 12 months (Table 2). There was a
highly significant interaction between OPV at birth and sex;
missing OPV was associated with a weak tendency for increased
mortality in girls, but significantly decreased mortality in boys
(Table 2). Adjustment for the background factors which were
associated with not having received OPV had essentially no impact
on the overall and sex-specific estimates or the interaction term
(Table 2). In other words, the association between OPV at birth
and sex meant that girls had 153% higher mortality than males in
the group that did not receive OPV at birth (female-male
MRR=2.53 (1.16–5.55)) but 20% lower mortality among children
who had received OPV at birth (0.80 (0.58–1.11)).
There were two major periods without OPV. Among children
enrolled from January 2004–June 2004, the overall adjusted
estimate was 0.72 (0.38–1.38); 0.52 (0.18–1.49) in boys and 0.87
(0.38–2.00) in girls. Among children enrolled from July 2004 and
until the end of the trial in November 2004 it was 0.62 (0.22–1.80);
0.24 (0.03–1.86) in boys and 1.22 (0.34–4.44) in girls.
The cumulative mortality curves for all children and for boys
and girls separately, are illustrated in Figures 2A–C. The effect of
not receiving OPV at birth on mortality up to 2 months of age (53
deaths) was 0.39 (0.12–1.29) among boys and 1.38 (0.54–3.57)
among girls (p=0.099). However, the effect of not receiving OPV
at birth was not limited to the first months of life, but appeared to
continue throughout the first year of life.
The effect of missing OPV at birth was the same in the vitamin
A and placebo groups (data not shown). The effect did not vary
with age at inclusion (data not shown). Furthermore, the effect did
not vary with place of enrolment (health centres versus hospital), or
by season (data not shown). The negative effect of missing OPV
was seen in boys of educated as well as mothers without any
schooling (data not shown), and in children with lower birth
weight and arm circumference as well as those without (data not
shown).
We studied the effect of missing OPV at birth on the major
causes of death: malaria, diarrhoea, respiratory diseases and
septicaemia; 58 deaths had other less common causes of death or
had no verbal autopsy conducted because the family had moved.
Though none of the differences reached statistical significance, the
sex-differential effect of OPV at birth was seen for all four major
causes of death (Table 3).
Hospitalisations
Among study children, a total of 366 hospitalisations took place
from enrolment to 12 months of age. We found no effect of
missing OPV at birth on the risk of hospitalisations within the first
year in either sex; the adjusted IRR among boys being 0.84 (0.59–
1.20) and 1.05 (0.68–1.63) among girls. The effect of missing OPV
at birth on hospital case-fatality also did not differ between boys
and girls, the adjusted relative risks being 1.04 (0.45–2.40) and
1.30 (0.55–3.07), respectively.
Discussion
The WHO recommends OPV at birth. The effect of OPV on
mortality has never been investigated. In our study, missing OPV
at birth was associated with significantly reduced mortality among
boys but a weak tendency for increased mortality among girls,
indicating that OPV at birth may have a sex-differential effect on
mortality.
Figure 1. Percentage of enrolled children who received OPV at birth during a vitamin A trial from 2002–2004 in Guinea-Bissau.
doi:10.1371/journal.pone.0004056.g001
OPV at Birth and Mortality
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The study was observational. Though it was a ‘‘natural
experiment’’ in the sense that it was logistic that determined the
availability of OPV there was nonetheless more children of
uneducated mothers and with low arm circumference who did not
receive OPV. These children may have had a higher risk of dying
during the first year of life a priori. However, control for maternal
education and arm circumference did not change the estimates
much. Also, if it was the less well-off children who did not receive
OPV, it would not explain the significantly lower mortality among
boys who did not receive OPV. In conclusion, we do not think that
there is any plausible uncontrolled background factor, which may
explain our observation.
Consistency of the findings
It strengthens the observation that the effect of not receiving
OPV was comparable during the two major independent periods
without OPV. Though no significant associations were observed
Table 1. The association between background factors and receiving OPV at birth.
No OPV at birth (N=962) OPV at birth (N=3383) P
N (%) N (%)
Male sex 503 (52%) 1697 (50%) P=0.245
Rainy season 262 (27%) 1892 (56%) P,0.0001
Suburb* P=0.048
Bandim 454 (47%) 1735 (51%)
Other 495 (51%) 1591 (47%)
Maternal school education* P,0.0001
Yes 586 (61%) 2065 (61%)
No 332 (35%) 930 (27%)
Maternal ethnicity* P=0.199
Pepel 254 (26%) 957 (28%)
Other 683 (71%) 2311 (68%)
Electricity* P=0.376
Yes 311 (32%) 1101 (33%)
No 627 (65%) 2168 (64%)
Place of enrolment P=0.065
Hospital 533 (55%) 1953 (58%)
Bandim HC 316 (33%) 1117 (33%)
Belem HC 113 (12%) 313 (9%)
Age at enrolment P=0.314
,1 week 576 (60%) 1996 (59%)
1–5 weeks 345 (36%) 1201 (36%)
6 weeks+ 41 (4%) 186 (6%)
Weight lowest quartile 159 (28%) 486 (24%) P=0.104
Arm circumferences lowest quartile 228 (24%) 565 (17%) P,0.0001
Randomised to vitamin A 482 (50%) 1663 (49%) P=0.604
*Figures do not add up due to lacking information.
doi:10.1371/journal.pone.0004056.t001
Table 2. The effect of missing OPV at birth on mortality up to 12 months of age.
No OPV at birth OPV at birth
No OPV vs. OPV MRR
(95% CI) (crude)
No OPV vs. OPV MRR (95%
CI) (adjusted)
MR (Deaths/pyrs) MR (Deaths/pyrs)
All 34.9 (30/859) 49.2 (149/3031) 0.71 (0.48–1.05) 0.69 (0.46–1.03)
Boys 20.0 (9/451) 54.1 (82/1514) 0.37 (0.18–0.73) 0.35 (0.18–0.71)
Girls 51.5 (21/408) 44.2 (67/1517) 1.16 (0.71–1.90) 1.14 (0.70–1.89)
P for interaction 0.008 0.006
*adjusted for season, suburb, maternal education, place of enrolment, lowest quartile arm circumference.
Note: MR=mortality rate, MRR=mortality rate ratio, pyrs=person-years of risk.
doi:10.1371/journal.pone.0004056.t002
OPV at Birth and Mortality
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hospitalization or hospital case-fatality, the pattern was the same.
For all major causes of death there was lower mortality for boys
and higher for girls if they had not received OPV; for both
hospitalization and case-fatality there was a 20–25% difference
between boys and girls which went in the same direction as the
overall result. Hence, the results are compatible with the
hypothesis that OPV at birth increases mortality of infant boys.
Many factors influence a mother’s choice to bring the child to the
hospital, and hospitalizations may not be the best proxy for severe
disease. The vast majority of children died outside the hospital.
Sex-differential effects
We have found sex-differential effects for almost all routine
vaccinations. Our previous studies of OPV did not show any
strong sex-differential effects [9,10]. In the present study the sex-
differential effect was pronounced and worrying because it
suggested a negative effect of OPV at birth in boys. We have no
biological explanation for the sex-differential effect. However, the
consistent observation of sex-differential effects on overall
mortality of routine vaccinations such as DTP and measles
vaccine does add plausibility to the hypothesis that boys and girls
may have different immune systems, which are affected in a
differential manner by our current interventions.
Conclusion
OPV given with BCG at birth became policy for logistic
reasons. Subsequently a single study showed that it may increase
antibody titres. The effect of providing OPV at birth on overall
mortality was never tested. Many routine vaccines have non-
specific effects on mortality that affects boys and girls differently.
This ‘‘natural experiment’’ suggests that the same may apply to
OPV administered with BCG at birth. Not receiving OPV at birth
was associated with a tendency for increased mortality in girls, but
significantly decreased mortality in boys. There is political interest
in substituting OPV with IPV [17]. However, this may take many
years. If OPV at birth has unwarranted effects in boys, provision of
OPV at birth to boys should be stopped since OPV at birth
probably contributes little to immunity. If OPV has beneficial
effects in girls, substituting with IPV may increase overall mortality
in girls. Randomised studies of the effect of providing OPV at birth
on overall mortality in both sexes are warranted.
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Figures 2. A–C. Cumulative mortality curves as a function of receiving OPV at birth or not, overall (A) and by sex (B,C).
doi:10.1371/journal.pone.0004056.g002
Table 3. The effect of missing OPV at birth on disease-specific mortality up to 12 months of age.
All No OPV versus OPV Adjusted MRR (95% CI)
Boys Girls
Malaria (35 deaths) 0.70 (0.28–1.73) 0.27 (0.03–2.06) 1.05 (0.38–2.91)
Diarrhoea (34 deaths) 1.21 (0.53–2.79) 0.53 (0.12–2.37) 2.12 (0.77–5.85)
Respiratory infection (26 deaths) 0.64 (0.21–1.89) N/A (0/503 vs. 10/1697) 1.23 (0.38–3.91)
Septicaemia (26 deaths) 1.15 (0.45–2.94) 0.99 (0.27–3.61) 1.35 (0.36–5.11)
*adjusted for season, suburb, maternal education, place of enrolment, lowest quartile arm circumference.
Note: MRR=mortality rate ratio.
doi:10.1371/journal.pone.0004056.t003
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